Product Description

Recombinant 2019-nCoV Guanine-N7 methyltransferase is produced by our E.coli expression system and the target gene encoding Ala1-Gln527 is expressed with a 6His tag at the N-terminus.Background:The nonstructural protein (nsp) 14 of SARS-CoV 2 was identified as a cap (guanine-N7)-methyltransferase (N7-MTase). Nsp14 of coronaviruses two different activities: an exoribonuclease activity acting on both ssRNA and dsRNA in a 3" to 5" direction and a N7-guanine methyltransferase activity. It may be involved in the proof-reading ability during the viral RNA replication and transcription. GTP, dGTP as well as cap analogs GpppG, GpppA and m7GpppG could be methylated by nsp14.positive-stranded RNA genome of the coronaviruses is translated from ORF1 to yield polyproteins that are proteolytically processed into intermediate and mature nonstructural proteins (nsps). SARS-CoV 2 polyproteins incorporate 16 protein domains (nsps). The putative non-structural protein 2 (nsp2) of SARS-CoV plays an important role in viral transcription and replication, and is an attractive target for anti-SARS drug development.Formulation:Supplied as a 0.2 μm filtered solution of PBS, 10% Glycerol, pH 7.4.Purity:> 85 % as determined by reducing SDS-PAGE.Endotoxin:< 1.0 EU per µg as determined by the LAL method.Shipping:This product is provided as liquid. It is shipped at frozen temperature with blue ice/gel packs. Upon receipt, store it immediately at<-20°C. Avoid freeze-thaw cycles.

More Details:Sequence:Ala1-Gln527Fusion Tag:N-6HisAccession:YP_009725309.1Species:VirusExpression System:E. coliMol Mass:62.9 kDaAP Mol Mass:60 kDaSynonyms:SARS-CoV 2 nsp14; SARS-CoV 2 ExoN; Guanine-N7 methyltransferaseDatasheet

FOR RESEARCH USE ONLY, NOT FOR USE IN DIAGNOSTIC PROCEDURES.Manufactured by: Elabscience

Questions about this product? Ready to place an order? Email us atorders@iwai-chem.comor give us a call: (650) 486-1541

Iwai-Chem我们的合作伙伴公司Bio Matrix Research，Inc.（BMR）正在申请专利，CELIXSYS™是一种新颖的单克隆抗体筛选方法（免疫沉淀等效系统），可保持抗原构象完整且表位不受空间位阻。  通过克服传统的基于固相的筛选方法（例如抗原包被的ELISA，斑点印迹或蛋白质印迹）的缺点，CELIXSYS™使我们能够获得适用于各种应用的卓越单克隆抗体，例如高灵敏度夹心ELISA，免疫色谱法或抗体阵列系统，以及免疫沉淀和蛋白质印迹。CELIXSYS™使得开发有益的单克隆抗体成为可能，而迄今为止，传统方法尚无法实现。展望未来，这项新技术的应用领域将继续从基础研究和临床诊断试剂扩展到抗体药物的探索。